Lilly's $3.8 Billion Vaccine Bets: A Quiet Shift Now
Lilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
This article outlines scenarios where target date funds may be preferable to index funds in a 401(k), focusing on simplicity and risk management.
26,105 articlesLilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
When a CEO sells a large block of stock, investors take notice. This article breaks down Ingredion's recent insider m...
Broadcom reported a strong Q1 FY2026 with AI-driven growth and a deep backlog, setting up a targeted, three-year broa...
A massive AI-driven data center build-out is changing how investors think about tech stocks. This piece explains the ...
Rigetti Computing shares jumped this week as momentum in quantum tech paired with company milestones. Learn the catal...
When an insider doubles down on a falling stock, investors sit up and take notice. This article breaks down what it c...
Nebius Group stunned investors with a strong May, signaling momentum in its AI cloud push. This guide breaks down wha...
A closer look at dividend aristocrats with multi-decade payout streaks and what their steady income track means for i...
STAG and EastGroup Properties stand out in the warehouse REIT space. This guide compares portfolio strategy, growth d...
Oracle is set to report its June quarter as AI demand tests the cloud backbone. Backlog and RPO could reveal real app...
As AI reshapes design tools, a Claude-powered tie-up could shift Figma's growth trajectory. This article breaks down ...
Jumia's Q1 2026 earnings call offers a clear view of how the company plans to scale across Africa. This article break...